Table 1. Summary of included studies and patient characteristics.
| First author and year | Country or region | No. of patients | Male/female | Stage and histology | Median or mean/SD or range of age (year) | Median/range of follow to up (month) | Sample and method | ERβ subcellular localization | ERβ expression high/low |
|---|---|---|---|---|---|---|---|---|---|
| Kawai 2005 | Japan | 132 | 76/56 | stage I–IV NSCLC (ADC/SCC/other 102/28/2) | 66 (38 to 81) | 0.01 to 60 | Tumor tissue IHC | Nuclear | 67/65 |
| Schwarz 2005 | United States | 216 | NR | stage I–III adenocarcinoma | 52.7 (±11.4)* | 16 (0.01 to 60) | Tumor tissue IHC | Nuclear | 128/88 |
| Wu 2005 | Taiwan | 301 | 174/127 | stage I–III NSCLC (ADC/SCC/other 194/90/17) | 63 (30 to 83) | 41 (2 to 168) | Tumor tissue IHC | Nuclear | 138/163 |
| Skov 2008 | Denmark | 104 | 71/33 | stage I–IIIB NSCLC (ADC/SCC/other 40/56/8) | NR | >180 | Tumor tissue IHC | Nuclear | 72/32 |
| Toh 2010 | Singapore | 106 | 63/43 | stage I–IV adenocarcinoma | 62 (54 to 69) | NR | Tumor tissue IHC | Overall | 10/96 |
| Mauro 2010 | Argentina | 57 | 40/18 | stage IA-IB NSCLC (ADC/SCC/other 18/33/6) | 65 (47 to 83) | 48 (3 to 116) | Tumor tissue IHC | Nuclear | 22/35 |
| Nose 2011 | Japan | 43 | 23/20 | stage IA–IV adenocarcinoma | 65.9 (45 to 85) | 1 to 25 | Tumor tissue IHC | Nuclear | 21/22 |
| Mah 2011 | United States | 60 | NR | stage IA–IV NSCLC (NR) | NR | 0.01 to 120 | Tumor tissue IHC | Overall/cytoplasmic | 26/34 |
| 190 | NR | NR | NR | Tumor tissue IHC | NR | ||||
| Stabile 2011 | United States | 183 | 92/91 | stage IA–IV NSCLC (ADC/SCC/other 103/62/18) | 68 (38 to 92) | 46 (0.01 to 172) | Tumor tissue IHC | Overall/cytoplasmic | 147/30 |
| 64/105 | |||||||||
| Monica 2012 | Italy | 106 | 79/27 | stage IIIA–IV NSCLC (ADC/SCC/other 57/34/15) | 66 | 1 to 36 | Tumor tissue IHC | Nuclear | NR |
| Navaratnam 2012 cohort 1 | Canada | 79 | 32/47 | stage I–IV NSCLC(NR) | 69.2 (45.7 to 85.2) | 1 to 36 | Tumor tissue IHC | Nuclear | 40/39 |
| Navaratnam 2012 cohort 2 | Canada | 47 | NR | stage I–IV NSCLC(NR) | 62.8 (38.4 to 74.1) | 1 to 25 | Tumor tissue IHC | Nuclear | 23/24 |
| Verma[1] 2012 | Japan | 162 | 98/64 | stage I–IV NSCLC (ADC/SCC/other 120/38/4) | 45 to 82) | 1 to 110 | Tumor tissue IHC | Cytoplasmic | 62/100 |
| Verma[2] 2012 | Japan | 169 | 103/66 | stage I–IV NSCLC (ADC/SCC/other 129/36/4) | NR | 1 to 111 | Tumor tissue IHC | Nuclear | 148/21 |
| He 2015 | China | 46 | 31/15 | stage IV NSCLC (ADC/SCC/other 33/13/0) | 58 (40 to 80) | 2 to 23 | Tumor tissue IHC | Cytoplasmic | 36/10 |
| Tanaka 2016 | Japan | 78 | 40/38 | stage IA–IIIB adenocarcinoma | 69 (36 to 84) | 66 (1 to 117) | Tumor tissue IHC | Nuclear | 59/19 |
| Gao 2017 | China | 62 | NR | stage II–IV NSCLC (NR) | NR | 1 to 74 | Tumor tissue IHC | Overall | 37/25 |
| Ding 2018 | China | 126 | 56/70 | stage IV adenocarcinoma | 62 (31 to 81) | 1 to 98 | Tumor tissue IHC | Cytoplasmic | 17/109 |
| Yu 2018 | China | 140 | 0/140 | stage I–IV adenocarcinoma | 56.7* | 1 to 60 | Tumor tissue IHC | Nuclear | 109/47 |
| Cheng 2018 | United States | 813 | 363/450 | stage IA–IIIB NSCLC (ADC/SCC/other 465/200/148) | NR | 62 | Tumor tissue IHC | Cytoplasmic/nuclear | NR |
| He 2019 | China | 201 | 56/145 | stage IV adenocarcinoma | 65 (27 to 84) | 1 to 32 | Tumor tissue IHC | Overall/nuclear | 98/103 |
| 99/102 | |||||||||
| Lee 2020 | Korea | 84 | 43/41 | stage IA-IIIB adenocarcinoma | 63.9 (±8.8)* | 1 to 99 | Tumor tissue IHC | Nuclear | 71/13 |
| Enwere | Canada | 299 | 150/149 | stage I–IV NSCLC (ADC/SCC/other 162/94/43) | 65 (33 to 88) | 0 to 90 | Tumor tissue Fluorescence IHC | Nuclear | 34/264 |
*, mean/SD of age. NR, not reported; NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SCC, squamous cell carcinomas; IHC, immunohistochemistry; ERβ, estrogen receptor beta; SD, standard deviation.